July 2, 2022

According to Lorenza Di Marco, PhD, immunotherapy treatment can increase the risk of liver rejection in patients with recurrent HCC who have undergone a liver transplant.

Ajai Chari, MD, explains oncologists should expect from the upcoming 40th Annual CFS Innovative Therapy for Tomorrow.

A presentation by Richard S. Finn, MD, during the American Association for Cancer Research Special Conference, focused on phase 3 combination studies in that setting.

Results from a phase 3 study of pembrolizumab and nadofaragene firadenovec in patients with BCG-unresponsive non–muscle invasive bladder cancer suggests that immune checkpoint inhibitors have synergy with antibody drug conjugates.

Findings from the ALCHEMIST trial indicate 53% of patients received adequate lymph node dissection and only 57% received adjuvant chemotherapy, despite indications for this treatment.

The phase 3 PADA-1 trial revealed a correlation between estrogen receptor- and progesterone receptor-positive metastatic breast cancer and prolonged progression-free survival.

Ashok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.

Results from the DS8201-A-U105 study showed that nivolumab added to trastuzumab deruxtecan has some benefit for patients with HER2-positive breast cancer.

The normal gut microbiota metabolizes nutrients and drugs, maintains the gut mucosal barrier integrity, protects against pathogens, and trains and develops the immune system. The gut microbiome has been implicated in many human pathologies.

Many clinicians believe the most significant advance in LBCL treatment in this time is the development of chimeric antigen receptor T-cell therapy.

Sonal Sura, MD, a radiation oncologist with GenesisCare in Naples, Florida, addresses the cause of this gap and outlines steps physicians can take to improve patient care for women.

Harnessing existing and otherwise safe antibody-targeting strategies and combining them with chemotherapy or other bioactive compounds or as a bispecific dual antibody moiety are an exciting strategy of protein engineering that is emerging and coming into its own in oncology.